|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American society of
clinical oncology/college of American pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morris GJ, Naidu S, Topham AK, Guiles F,
Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K and
Mitchell EP: Differences in breast carcinoma characteristics in
newly diagnosed African-American and Caucasian patients: A
single-institution compilation compared with the national cancer
institute's surveillance, epidemiology, and end results database.
Cancer. 110:876–884. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sedighi Pashaki A, Sheida F, Moaddab Shoar
L, Hashem T, Fazilat-Panah D, Nemati Motehaver A, Ghanbari Motlagh
A, Nikzad S, Bakhtiari M, Tapak L, et al: A randomized, controlled,
parallel-group, trial on the long-term effects of melatonin on
fatigue associated with breast cancer and its adjuvant treatments.
Integr Cancer Ther. 22:153473542311686242023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moezian GSA, Javadinia SA, Sales SS,
Fanipakdel A, Elyasi S and Karimi G: Oral silymarin formulation
efficacy in management of AC-T protocol induced hepatotoxicity in
breast cancer patients: A randomized, triple blind,
placebo-controlled clinical trial. J Oncol Pharm Pract. 28:827–835.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Salek R, Dehghani M, Mohajeri SA, Talaei
A, Fanipakdel A and Javadinia SA: Amelioration of anxiety,
depression, and chemotherapy related toxicity after crocin
administration during chemotherapy of breast cancer: A double
blind, randomized clinical trial. Phytother Res. 35:5143–5153.
2021. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fazilat-Panah D, Vakili Ahrari Roudi S,
Keramati A, Fanipakdel A, Sadeghian MH, Homaei Shandiz F,
Shahidsales S and Javadinia SA: Changes in cytokeratin 18 during
neoadjuvant chemotherapy of breast cancer: A prospective study.
Iran J Pathol. 15:117–126. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Swami U, Chaudhary I, Ghalib MH and Goel
S: Eribulin-a review of preclinical and clinical studies. Crit Rev
Oncol Hematol. 81:163–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mani S and Swami U: Eribulin mesilate, a
halichondrin B analogue, in the treatment of breast cancer. Drugs
Today (Barc). 46:641–653. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cortes J, O'Shaughnessy J, Loesch D, Blum
JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V,
Delozier T, et al: Eribulin monotherapy versus treatment of
physician's choice in patients with metastatic breast cancer
(EMBRACE): A phase 3 open-label randomised study. Lancet.
377:914–923. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kaufman PA, Awada A, Twelves C, Yelle L,
Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE and Cortes J: Phase
III open-label randomized study of eribulin mesylate versus
capecitabine in patients with locally advanced or metastatic breast
cancer previously treated with an anthracycline and a taxane. J
Clin Oncol. 33:594–601. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ghosh S: Cisplatin: The first metal based
anticancer drug. Bioorg Chem. 88:1029252019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang C, Xu C, Gao X and Yao Q:
Platinum-based drugs for cancer therapy and anti-tumor strategies.
Theranostics. 12:2115–2132. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin C, Cui J, Peng Z, Qian K, Wu R, Cheng
Y and Yin W: Efficacy of platinum-based and non-platinum-based
drugs on triple-negative breast cancer: meta-analysis. Eur J Med
Res. 27:2012022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ko H, Lee M, Cha E, Sul J, Park J and Lee
J: Eribulin mesylate improves cisplatin-induced cytotoxicity of
triple-negative breast cancer by extracellular signal-regulated
kinase 1/2 activation. Medicina (Kaunas). 58:4572022.
|
|
18
|
Obidiro O, Battogtokh G and Akala EO:
Triple Negative breast cancer treatment options and limitations:
Future outlook. Pharmaceutics. 15:17962023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Swami U, Shah U and Goel S: Eribulin in
cancer treatment. Mar Drugs. 13:5016–5058. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Terashima M, Sakai K, Togashi Y, Hayashi
H, De Velasco MA, Tsurutani J and Nishio K: Synergistic antitumor
effects of S-1 with eribulin in vitro and in vivo for
triple-negative breast cancer cell lines. Springerplus. 3:4172014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kuznetsov G, Towle MJ, Cheng H, Kawamura
T, TenDyke K, Liu D, Kishi Y, Yu MJ and Littlefield BA: Induction
of morphological and biochemical apoptosis following prolonged
mitotic blockage by halichondrin B macrocyclic ketone analog E7389.
Cancer Res. 64:5760–5766. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okouneva T, Azarenko O, Wilson L,
Littlefield BA and Jordan MA: Inhibition of centromere dynamics by
eribulin (E7389) during mitotic metaphase. Mol Cancer Ther.
7:2003–2011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ono H, Sowa Y, Horinaka M, Iizumi Y,
Watanabe M, Morita M, Nishimoto E, Taguchi T and Sakai T: The
histone deacetylase inhibitor OBP-801 and eribulin synergistically
inhibit the growth of triple-negative breast cancer cells with the
suppression of survivin, Bcl-xL, and the MAPK pathway. Breast
Cancer Res Treat. 171:43–52. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ono H, Horinaka M, Sukeno M, Morita M,
Yasuda S, Nishimoto E, Konishi E and Sakai T: Novel RAF/MEK
inhibitor CH5126766/VS-6766 has efficacy in combination with
eribulin for the treatment of triple-negative breast cancer. Cancer
Sci. 112:4166–4175. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang X, Martindale JL and Holbrook NJ:
Requirement for ERK activation in cisplatin-induced apoptosis. J
Biol Chem. 275:39435–39443. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guégan JP, Ezan F, Théret N, Langouët S
and Baffet G: MAPK signaling in cisplatin-induced death:
Predominant role of ERK1 over ERK2 in human hepatocellular
carcinoma cells. Carcinogenesis. 34:38–47. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choi BK, Choi CH, Oh HL and Kim YK: Role
of ERK activation in cisplatin-induced apoptosis in A172 human
glioma cells. Neurotoxicology. 25:915–924. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arany I, Megyesi JK, Kaneto H, Price PM
and Safirstein RL: Cisplatin-induced cell death is EGFR/src/ERK
signaling dependent in mouse proximal tubule cells. Am J Physiol
Renal Physiol. 287:F543–F549. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Giltnane JM and Balko JM: Rationale for
targeting the Ras/MAPK pathway in triple-negative breast cancer.
Discov Med. 17:275–283. 2014.PubMed/NCBI
|
|
31
|
Sivaprasad U and Basu A: Inhibition of ERK
attenuates autophagy and potentiates tumour necrosis
factor-alpha-induced cell death in MCF-7 cells. J Cell Mol Med.
12:1265–1271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu S, Cao Z, Cai F, Yao Y, Chang X, Wang
X, Zhuang H and Hua ZC: ADT-OH exhibits anti-metastatic activity on
triple-negative breast cancer by combinatorial targeting of
autophagy and mitochondrial fission. Cell Death Dis. 15:4632024.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Han Y, Fan S, Qin T, Yang J, Sun Y, Lu Y,
Mao J and Li L: Role of autophagy in breast cancer and breast
cancer stem cells (review). Int J Oncol. 52:1057–1070.
2018.PubMed/NCBI
|
|
34
|
Eisenberg-Lerner A, Bialik S, Simon HU and
Kimchi A: Life and death partners: Apoptosis, autophagy and the
cross-talk between them. Cell Death Differ. 16:966–975. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rosenfeldt MT and Ryan KM: The multiple
roles of autophagy in cancer. Carcinogenesis. 32:955–963. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li X, He S and Ma B: Autophagy and
autophagy-related proteins in cancer. Mol Cancer. 19:122020.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gewirtz DA: The four faces of autophagy:
Implications for cancer therapy. Cancer Res. 74:647–651. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
World Health Organization, . Global breast
cancer initiative implementation framework: Assessing,
strengthening and scaling up of services for the early detection
and management of breast cancer: Executive summary. Geneva: World
Health Organization; 2023
|
|
39
|
Arnold M, Morgan E, Rumgay H, Mafra A,
Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S
and Soerjomataram I: Current and future burden of breast cancer:
Global statistics for 2020 and 2040. Breast. 66:15–23. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Goldstein DA, Chen Q, Ayer T, Howard DH,
Lipscomb J, El-Rayes BF and Flowers CR: First- and second-line
bevacizumab in addition to chemotherapy for metastatic colorectal
cancer: A United States-based cost-effectiveness analysis. J Clin
Oncol. 33:1112–1118. 2015. View Article : Google Scholar : PubMed/NCBI
|
